Drug Choice Might Matter for Patients With Macular Degeneration
WEDNESDAY, Dec. 7, 2022 (HealthDay News) — One of the two most common drugs used to treat age-related macular degeneration (AMD) appears better than the other, a new, small study suggests. Among 106 patients with “wet” age-related macular degeneration, 50% of those treated with aflibercept (Eylea) could be weaned offContinue Reading










